FDA Approves New Orphan Drug for Treatment of Rare Inflammatory Syndromes
Arcalyst is first treatment for extremely rare condition called Cryopyrin-Associated Periodic Syndrome or CAPS
The U.S. Food and Drug Administration today approved a drug to help ease the suffering faced by those with certain chronic inflammatory diseases. Arcalyst (rilonacept, an Interleukin-1 blocker) is now approved for the long term treatment of two Cryopyrin-Associated Periodic Syndromes (CAPS) disorders: Familial Cold Auto-Inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).
Symptoms of both of these disorders include inflammation such as joint pain, rash or skin lesions, fever and …read more